By Stephen S. Hall, New York Magazine, Oct. 20 online & Oct. 28 issue cover story
The article investigates prices like these
Avastin, $5,000/month; Zaltrap, $11,000/month; Yervoy, $39,000/month; Provenge, $93,000/course of treatment; Erbitux, $8,400/month; Gleevec, $92,000/year; Tasigna, $115,000/year; Sprycel, $123,000/year.
how they got that way, how some oncologists are finally ganging up to protest against them, how this has ultimately been caused by Medicare's approval process, and how other countries have handled it differently.